Radiobiology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA 94118, USA.
Anticancer Res. 2010 Mar;30(3):937-44.
A novel camptothecin derivative (TLC388) with higher efficacy and reduced toxicity has been synthesized and tested as a novel chemoradiosensitizing agent. This study investigated the mechanisms of the chemoradiosensitizing effects of TLC388 on H23 human non-small cell lung cancer (NSCLC) cells. Using the TUNEL assay, a significantly higher percentage of apoptotic cells was observed in the group treated with TLC388 plus X-ray radiation than those in groups treated with drug or radiation alone. The sensitizer enhancement ratio (SER) was 1.91. Apoptosis increased with drug concentration and radiation dose, exhibiting dose-dependent pattern. The results suggested that apoptosis could be a main mode of cell death that might underlie the increased chemoradio-sensitization of TLC388. Treatment with 30 nM of TLC388 plus 4 Gy X-ray also produced up to 42% of necrotic cells that were measured by trypan blue exclusion assay, but with TLC388 alone or 4 Gy radiation alone 9.8% or 11.1% necrotic cells were detected, respectively. An immunofluorescent staining method was employed to determine the levels of gamma-H2AX (phosphorylated H2AX, a variant of the H2A protein family, which is a component of the histone octomer in nucleosomes and is phosphorylated by kinases like ATM and ATR in the PI3K pathway, as the first step in recruiting and localizing DNA repair proteins) as a molecular biomarker of DNA double strand breaks (DSBs) in cells treated with TLC388 +/-radiation, or radiation alone. The formation of gamma-H2AX foci was observed after TLC388 or radiation exposure and when the cells were treated with 30 nM TLC388 plus radiation at a dose of 2 Gy, the percentage of cells containing gamma-H2AX foci increased significantly. Even more interesting, a markedly higher percentage (65.4%) of mitotic cells displayed gamma-H2AX foci after treatment with 30 nM TLC388 plus 0.5 Gy radiation, compared to only 5.9% or 26.1% of the M-phase cells treated with 30 nM TLC388 alone or 0.5 Gy radiation alone, respectively. It is suggested that mitotic cells become very sensitive to the production of DSBs after TLC388-radiation combined treatment and the formation of DSBs is strongly suggested to lead to the induction of apoptosis at doses lower than 4 Gy and to some necrosis at doses of 4 Gy or above. TLC388 enhances the production of DSBs and inhibits their repair, which contributes to the elucidation of the mechanisms of chemoradiosensitization of TLC388 and its development as a novel chemoradiosensitizing drug for improved radiotherapy.
一种新型喜树碱衍生物(TLC388)具有更高的疗效和更低的毒性,已被合成并测试为新型化学增敏放射治疗剂。本研究探讨了 TLC388 对 H23 人非小细胞肺癌(NSCLC)细胞的化学增敏放射作用的机制。通过 TUNEL 检测,与单独用药或单独照射组相比,用 TLC388 加 X 射线照射的细胞中凋亡细胞的比例明显更高。增敏比(SER)为 1.91。凋亡随药物浓度和辐射剂量的增加而增加,表现出剂量依赖性模式。结果表明,凋亡可能是细胞死亡的主要方式,可能是 TLC388 增强化学增敏作用的基础。用 30 nM TLC388 加 4 Gy X 射线处理也产生了高达 42%的台盼蓝排斥试验测量的坏死细胞,但单独用 TLC388 或 4 Gy 辐射分别检测到 9.8%或 11.1%的坏死细胞。免疫荧光染色法用于测定 γ-H2AX(磷酸化 H2AX,H2A 蛋白家族的一种变体,是核小体中组蛋白八聚体的组成部分,在 PI3K 途径中由 ATM 和 ATR 等激酶磷酸化,作为募集和定位 DNA 修复蛋白的第一步)作为 TLC388 +/-辐射处理或单独辐射处理的细胞中 DNA 双链断裂(DSB)的分子生物标志物。在用 TLC388 或辐射暴露后观察到 γ-H2AX 焦点的形成,当用 30 nM TLC388 加 2 Gy 辐射处理时,含有 γ-H2AX 焦点的细胞百分比显著增加。更有趣的是,与单独用 30 nM TLC388 或单独用 0.5 Gy 辐射处理的有丝分裂细胞相比,在用 30 nM TLC388 加 0.5 Gy 辐射处理的有丝分裂细胞中,有丝分裂细胞中 γ-H2AX 焦点的比例明显更高(65.4%)。这表明 TLC388-辐射联合治疗后,有丝分裂细胞对 DSB 的产生非常敏感,并且强烈提示 DSB 的形成导致在低于 4 Gy 的剂量下诱导凋亡,并在 4 Gy 或更高剂量下导致一些坏死。TLC388 增强 DSB 的产生并抑制其修复,这有助于阐明 TLC388 的化学增敏作用机制及其作为新型化学增敏放射治疗药物的发展,以提高放射治疗效果。